Protalix Biotherapeutics, Inc.
2 Snunit Street, Science Park
P.O. Box 455
Karmiel
21000
Tel: 972-4-988-9488
Fax: 972-4-988-9489
Website: http://www.protalix.com/
Email: info@protalix.com
291 articles about Protalix Biotherapeutics, Inc.
-
Protalix Biotherapeutics Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
4/18/2007
-
AMEX Lists Common Stock of Protalix Biotherapeutics
3/12/2007
-
Protalix Biotherapeutics to Commence Trading on the AMEX
3/9/2007
-
Orthodontix, Inc. Announces Name Change to Protalix Biotherapeutics
3/1/2007
-
Protalix Biotherapeutics's Board Of Directors Approves The Closing Of The Merger With Orthodontix, Inc.
12/20/2006
-
Orthodontix, Inc. Announces Completion Of Actions Required For Protalix Biotherapeutics Merger
12/19/2006
-
Teva Pharmaceutical Industries Limited And Protalix Biotherapeutics Announce A Collaboration Agreement For The Development Of Two Biopharmaceuticals, Based On Protalix Biotherapeutics's Recombinant Plant Cell Expression Technology
9/26/2006
-
Protalix Biotherapeutics Announces Sale Of Shares
9/14/2006
-
Dr. Philip Frost Leads Up To $21 Million Investment In Protalix Biotherapeutics
8/23/2006
-
The Day In Review: FDA Cancels Meeting For Wyeth Psych Drug
8/22/2006
-
Orthodontix, Inc. And Protalix Biotherapeutics Announce Merger Agreement; $15 Million To Be Invested In Protalix Biotherapeutics
8/22/2006